Cell Therapeutics Readies Commercial Launch of Pixuvri® in EU
News Dec 26, 2012
Cell Therapeutics, Inc. has announced that it is re-aligning its resources and re-prioritizing its product development pipeline to focus on the launch of Pixuvri in the EU and accelerate the advancement of pacritinib, CTI's recently-acquired, highly-selective JAK 2 inhibitor, into phase III clinical trials.
As a result, CTI's operating burn rate will be reduced from an average of $6.5 million per month to an average of $4.5 million per month.
"In-market research across the five largest EU markets confirms significant physician interest in product adoption in the target patient population. With the potential to generate meaningful Pixuvri® product sales, coupled with the recent acquisition of pacritinib and investigator interest in participating in its pivotal studies, we believe that focusing our resources on the Pixuvri launch and accelerating the start of pacritinib phase III studies is the best deployment of our limited resources to build near-term shareholder value," said James A. Bianco, M.D., Chief Executive Officer of CTI.
"We are re-evaluating the tostedostat phase III clinical trial design and are considering both studies in a refractory setting and in front line treatment," said Steven E. Benner, M.D., M.H.S, CMO of CTI.
Benner continued, "With two ongoing phase II investigator-sponsored trials examining the activity of combining tosedostat with hypomethylating agents (HMAs), we should have adequate data to make an evidence-based decision on the trial design with the highest probability of both regulatory and commercial success by early next year."
Tailor-made Protein Fights Several Species of BacteriaNews
As resistance to existing antibiotics increases, new approaches to serious bacterial infections are needed. Now researchers have investigated one such alternative.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE